	Application No.	Applicant(s)	
Notice of Allowability	09/458,366	EVANS ET AL.	
	Examiner	Art Unit	
	Joseph T. Woitach	1632	
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS ( herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIG of the Office or upon petition by the applicant. See 37 CFR 1.313	OR REMAINS) CLOSED in or other appropriate comm GHTS. This application is a	n this application. If not included unication will be mailed in due course. <b>TH</b>	
1. This communication is responsive to 8/25/2004.			
2. ☑ The allowed claim(s) is/are <u>13-19,21-31 and 34-42</u> .			
3. ☑ The drawings filed on <u>09 December 1999</u> are accepted by	the Examiner.		
<ul> <li>4. Acknowledgment is made of a claim for foreign priority un</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have</li> <li>2. Certified copies of the priority documents have</li> <li>3. Copies of the certified copies of the priority documents have</li> <li>International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>	been received. been received in Application	on No	· le
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5.   A SUBSTITUTE OATH OR DECLARATION must be submi	ENT of this application.		
INFORMAL PATENT APPLICATION (PTO-152) which give			
<ol> <li>CORRECTED DRAWINGS (as "replacement sheets") mus         <ul> <li>(a) including changes required by the Notice of Draftsperse</li> <li>1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the deposition of the dep</li></ul></li></ol>	on's Patent Drawing Review Amendment / Comment o  84(c)) should be written on the header according to 37 Ci	r in the Office action of he drawings in the front (not the back) of R 1.121(d).	
attached Examiner's comment regarding REQUIREMENT F			
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview S Paper No. 8), 7. ☒ Examiner's	formal Patent Application (PTO-152) ummary (PTO-413), /Mail Date Amendment/Comment Statement of Reasons for Allowance	

Application/Control Number: 09/458,366

Art Unit: 1632

## **DETAILED ACTION**

This application is a continuation in part of 09/227,718, filed 1/8/99, which is a continuation in part of application 09/005,286, filed 1/9/98, now allowed.

Applicants' amendment filed August 25, 2004, has been received and entered. Claims 1-12, 20, 32, 33 have been canceled. Claims 13, 14, 17, 24, 25, 28, 31, 35, 37-39, 41 and 42 have been amended. Claims 13-19, 21-31, 34-42 are pending and currently under examination.

## Specification

The Applicants have argued that the nucleotide sequence disclosure contained in this application complies with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825. Upon review of the sequences in the claims, polynucleotide sequences lest than 10 base pairs long, the Examiner agrees that the application is in sequence compliance

## Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

As indicated previously, the claims are free of the art of record because the prior art of record fails to teach or suggest the human SXR polynucleotide or polypeptide as set forth in the specific SEQ IDs with the specific biological activities set forth in the independent claims.

Further, the SXR is a member of an orphan receptor family and the art fails to specifically teach or suggest the biological activities of the encoded polypeptide or the resulting phenotypes when expressed under the albumin promoter/enhancer in transgenic mice. The amendments to the

Application/Control Number: 09/458,366

Art Unit: 1632

Page 3

claims has addressed each of the remaining basis of rejection narrowing the scope of the claims to that which is considered fully described and enabled in view of the state of the art, and has

provided claim language consistent with that other related applications.

Any comments considered necessary by applicant must be submitted no later than the

payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for

Allowance."

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Deborah Reynolds, can be reached at (571) 272-0734.

Any inquiry of a general nature or relating to the status of this application should be

directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

Joseph T. Woitach

HENTEN PROTECTION

HU1632